The CheckMate 040 study presented the efficacy and safety of nivolumab (an anti-PD-1 inhibitor) in combination with ipilimumab (a CTLA-4 inhibitor) in advanced HCC. This evidence concerns the gene CTLA4 and hepatocellular carcinoma.